Vilacto Bio Inc. speeds up cooperation with Pharma GP to reach higher targets

COPENHAGEN, Denmark, Nov. 22, 2017 (GLOBE NEWSWIRE) -- Vilacto Bio Inc. (OTC QB:VIBI), is pleased to announce that within the next 3 month, the company will be taking over the online sales from Pharma GP direct to customers outside of the US. After having built its e commerce portal, www.vilacto.com, the company is ready to manage sales in higher volume and is targeting 8 figure annual sales from the portal in the near term. These sales are expected to come direct and through the company's affiliate program. The company is making this cooperation to streamline the sales and marketing of its existing Vilact skin care products, its new anti- aging cosmetic line and in preparation of its new skin care product: Carmen Electra by Vilact. which are expected to be launched within the next 6 months. All products will contain Lactoactive® ?The Molecule? that is making the difference on skin issues as well as smoothing, moisturizing and beautifying those who use it.

With this new sales arrangement of the e commerce portal (www.vilacto.com), the company's products will be available all over the globe to provide a better alternative to existing products on the market.

?This is another important step in our evolution as a public company and we are pleased to make this announcement," states Gert Anderson, CEO of Vilacto Bio Inc.

.About Vilacto Bio Inc.:

Vilacto Bio Inc. (OTC QB:VIBI) is a cosmeceutical and biotech company that has exclusive rights to the fully patented Lactoactive^® molecule, which in numerous studies has demonstrated above average effect in treating conditions such as inflammatory diseases, diabetes, psoriasis, skin aging, and skin issues in different levels. The Company also developed and markets a consumer skincare line under the Vilact® trademark.  The Company aims to further develop its Lactoactive^® molecule for the purpose of increasing the quality of its retail and medical skin cream products as well as licensing its Lactoactive^® molecule to the pharmaceutical industry.

Vilacto Bio Inc.
Fabriksvej 48
4700 Naestved
Denmark

Gert Andersen
Phone: +1 646-893-7895
[email protected]
www.vilactobio.com     

Forward-Looking Statements & Disclaimers:

The information in this Press Release includes certain "forward-looking" statements within the meaning of the Safe Harbor provisions of Federal Securities Laws, as that term is defined in section 27a of the United States Securities Act of 1933, as amended, and section 21e of the United States Securities Exchange Act of 1934, as amended. Statements in this document, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Investors are cautioned that such statements are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including the future financial performance of the Company. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release, and the Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.